Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of proline-based canagliflozin tablets in type 2 diabetes mellitus
ChiCTR2500109827Phase 4Not yet recruiting
- Sponsor
- Affiliated Hospital of Guizhou Medical University
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of canagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Affiliated Hospital of Guizhou Medical University. Primary endpoint: Glycated hemoglobin (HbA1c). Planned start Sep 2025; status: not yet recruiting.
02
Drugs
canagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2500109827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109827.